• A non-invasive Dexcom for glucose monitoring.
• Like an Apple Watch or Fitbit that measures blood glucose non-invasively.

• Bio-RFID Technology: A proprietary technology that uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature.
• Glucose Monitor: A product that applies Bio-RFID technology to provide users with real-time information on their blood glucose levels.

• Individuals with Diabetes: This includes people diagnosed with Type 1 or Type 2 diabetes who require continuous or frequent monitoring of their blood glucose levels to manage their condition, adjust medication, and make informed lifestyle choices.
• Pre-diabetic Individuals: Those who have elevated blood glucose levels but are not yet diabetic, or individuals at high risk of developing diabetes, may use the monitor for preventative health management and to track the impact of diet and exercise on their glucose levels.
• Health-Conscious Individuals: Some individuals, even without a diabetes diagnosis, may be interested in real-time glucose monitoring to optimize their diet, exercise, and overall metabolic health for performance, weight management, or general well-being.

Robert Gregory Kidd, Chief Executive Officer and Chairman of the Board

Mr. Kidd was appointed CEO and Chairman of USBC, Inc. in August 2025, following a strategic acquisition by Goldeneye 1995 LLC, an affiliate of Mr. Kidd, which established a new vision for the company focused on digital financial technologies. He is a serial entrepreneur and investor, having founded Hard Yaka, Inc. (2010), Apto Payments Inc. (2014), 3taps, Inc., Global ID Framework, Inc., and Omnumi. Mr. Kidd has been an early investor and advisor in numerous successful companies including Twitter, Square (Block), Coinbase, Robinhood, Solana, Ripple, Uphold, and Brave. He co-founded DMSC with Linda Jenkinson and took the company public on Nasdaq, which reached $250 million in revenue and 3,200 staff globally. His past roles include Senior Director at Promontory Financial Group LLC, Analyst at the Federal Reserve System (in payments), and Chief Risk Officer at Ripple Labs Inc. He is also the majority shareholder in Vast Bank Holdings.

Kitty B. Payne, Treasurer, Secretary, Chief Financial Officer and Principal Accounting Officer

Ms. Payne serves as the Chief Financial Officer, Treasurer, Secretary, and Principal Accounting Officer of USBC, Inc. No further background information is available in the provided search results.

Ronald P. Erickson, Director, Senior Vice President and President, Science Division

Mr. Erickson is the founder of Know Labs, the predecessor company to USBC, Inc., and continues to lead its legacy science and research activities. He possesses over 30 years of board, business development, financial, and executive leadership experience across industries including therapeutics, mobile technologies, and software. He co-founded Microrim in 1981 and was an original investor in Egghead Software, where he served in various capacities including chairman, vice-chairman, and interim CEO. Mr. Erickson founded or served as an executive for companies such as GlobalTel Resources, Inc., Egghead Software, Inc., eCharge Corporation, and Blue Frog Media. Notably, he was the sole angel investor in Double Down Interactive, a social video game studio, which was acquired by International Game Technology (IGT) for up to $500 million in 2012.

James H. Anderson, Chief Medical Officer and Chairman of Medical, Scientific & Regulatory Advisory Board

Dr. Anderson has served as Chief Medical Officer and Chairman of the Medical, Scientific & Regulatory Advisory Board since 2018. He previously held roles as Chief Medical Leader for Diabetes and Endocrinology at Eli Lilly, Chief of Medicine at the U.S. Army Medical Research Institute for Infectious Diseases, a Director at Generex, and Medical Director at Catapult Health. He continues to lead all activities related to clinical development for the company.

Dominic Klyve, Chief Science Officer

Dr. Klyve serves as the Chief Science Officer. He is a recognized author of more than 80 peer-reviewed publications in science and mathematics and has acted as Principal Investigator on grants, including those from the National Science Foundation, totaling over $1.5 million. Dr. Klyve is a winner of the Henry A. Alder Award and the Lester Ford Award from the Mathematical Association of America and holds a professorship at Central Washington University. He was welcomed to the senior management team of Know Labs in November 2024 and previously served as a lead data scientist and consultant for the company.

The key risks to USBC (formerly Know Labs, Inc.) are primarily related to its financial stability, the challenging regulatory pathway for its core product, and intense market competition.

1. Financial Instability and Going Concern: USBC faces significant financial challenges, as evidenced by a net loss of $4.67 million in Q1 FY2025 and an audit opinion with a "going concern" explanation for FY2024, indicating substantial doubt about the company's ability to continue operations for the next twelve months. The company also received a non-compliance notice from NYSE American in late 2024 due to its equity levels falling below required thresholds, although the trading suspension was later lifted. Despite having an S-3 shelf offering for potential capital access, sustained losses and cash burn represent a critical risk to its long-term viability and ability to fund ongoing research, development, and commercialization efforts.
2. Regulatory Approval of Non-Invasive Glucose Monitor: USBC's primary focus is on developing and commercializing a non-invasive glucose monitor using its Bio-RFID technology, which requires U.S. Food and Drug Administration (FDA) clearance before it can be introduced to the market. The FDA has yet to approve any truly non-invasive devices for measuring blood sugar, making the regulatory pathway exceptionally challenging and lengthy. While the company is conducting internal trials and working to refine its algorithms to meet accuracy requirements, there is no guarantee of successful FDA clearance.
3. Intense Competition in the Glucose Monitoring Market: Should USBC successfully obtain FDA approval for its non-invasive glucose monitor, it would enter a highly competitive market dominated by established industry players such as Dexcom, Abbott Laboratories, Senseonics, and Medtronic. Differentiating its product, gaining market share, and achieving commercial success against these entrenched competitors with significant resources and existing market penetration would be a substantial hurdle.

The potential for major technology companies, such as Apple, to successfully develop and launch their own highly integrated, non-invasive continuous glucose monitoring solutions poses a significant emerging threat. These companies possess immense research and development resources, established user ecosystems, and substantial market reach, which could rapidly dominate the non-invasive glucose monitoring space and displace smaller, specialized companies.

Know Labs, Inc. (USBC) focuses on developing and commercializing a non-invasive glucose monitor utilizing its proprietary Bio-RFID technology. This technology allows for real-time blood glucose level information through spectroscopy, without needing to pierce the skin. The addressable markets for this main product can be assessed through the lens of both the non-invasive glucose meter market and the broader continuous glucose monitoring (CGM) market.

For the non-invasive blood glucose monitoring system market, the global market revenue was valued at approximately USD 33.07 million in 2024 and is projected to increase to USD 253.69 million by 2034, demonstrating a compound annual growth rate (CAGR) of 22.6% during this forecast period. North America dominated this market in 2023.

Within the wider continuous glucose monitoring (CGM) market, which encompasses both invasive and non-invasive technologies, the global market was valued at USD 10.9 billion in 2024 and is projected to grow to USD 47.1 billion by 2034, at a CAGR of 16%. North America holds the largest share of this global market, accounting for 47.1% in 2024.

Specifically for the U.S. continuous glucose monitoring market, the size was estimated at USD 4.9 billion in 2024. This market is expected to expand to USD 22 billion by 2034, with a CAGR of 16.2%.

Know Labs itself anticipates becoming the world's first FDA-cleared non-invasive glucose monitor in a global market that they project to be over USD 21 billion once their product secures FDA clearance.

Share Issuance

• In August 2025, Know Labs, Inc. (then KNW) issued approximately 357.8 million new common shares at $0.335 per share to Goldeneye 1995 LLC, resulting in significant dilution.
• Shareholders approved an amendment to increase the number of authorized common stock from 7.5 million to 750 million in July 2025.
• In February 2025, Know Labs completed a registered direct offering for $300,000, and also announced a $1.655 million public offering and closed a $3.445 million public offering in late 2024.

Inbound Investments

• Goldeneye 1995 LLC, an affiliate of Greg Kidd, acquired a controlling interest in Know Labs in August 2025, contributing 1,000 Bitcoin and $15 million in cash, in a transaction valued at approximately $125 million.
• The cash received from this strategic acquisition was used to retire existing debt, redeem outstanding preferred equity, and provide working capital.
• An $18 million S-3 shelf registration statement, effective January 2024, was put in place to raise additional funds through equity, preferred stock, and convertible debentures.

Outbound Investments

• Following the strategic acquisition in August 2025, USBC (formerly Know Labs, Inc.) adopted a Bitcoin treasury strategy, holding approximately 1,015 Bitcoin valued at $89.5 million as of December 30, 2025.
• This Bitcoin treasury is managed by a third-party asset manager for yield generation.

Capital Expenditures

• For the fiscal year ended September 30, 2024, cash used in operations totaled $12.8 million, with $6.1 million specifically allocated to product development.
• Know Labs developed and announced a working prototype of its KnowU™ non-invasive wearable continuous glucose monitor by March 2024, which is undergoing further internal development and testing.
• Proceeds from a proposed offering of 3 million shares, as per an S-1 filing (pre-September 2022 uplisting), were intended for research and development, sales and marketing, general and administrative expenses, capital investments, and working capital.